A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants with Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Recruiting

Phase 1

Phase 2

Sponsor:

A2 Biotherapeutics Inc.

Code:

NCT05736731

Conditions

Solid Tumor, Adult

Solid Tumor

Pancreatic Cancer

Pancreatic Neoplasms

Pancreas Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

A2B530

xT-Onco with HLA-LOH Assay

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information